Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 37

Cited In for PubMed (Select 18803326)

1.

Combinatorial therapy with tamoxifen and trifluoperazine effectively inhibits malignant peripheral nerve sheath tumor growth by targeting complementary signaling cascades.

Brosius SN, Turk AN, Byer SJ, Longo JF, Kappes JC, Roth KA, Carroll SL.

J Neuropathol Exp Neurol. 2014 Nov;73(11):1078-90. doi: 10.1097/NEN.0000000000000126.

PMID:
25289889
2.

TAGLN expression is upregulated in NF1-associated malignant peripheral nerve sheath tumors by hypomethylation in its promoter and subpromoter regions.

Park GH, Lee SJ, Yim H, Han JH, Kim HJ, Sohn YB, Ko JM, Jeong SY.

Oncol Rep. 2014 Oct;32(4):1347-54. doi: 10.3892/or.2014.3379. Epub 2014 Aug 4.

3.

Translationally controlled tumor protein is a novel biological target for neurofibromatosis type 1-associated tumors.

Kobayashi D, Hirayama M, Komohara Y, Mizuguchi S, Wilson Morifuji M, Ihn H, Takeya M, Kuramochi A, Araki N.

J Biol Chem. 2014 Sep 19;289(38):26314-26. doi: 10.1074/jbc.M114.568253. Epub 2014 Aug 4.

PMID:
25092287
4.

Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.

Watson AL, Anderson LK, Greeley AD, Keng VW, Rahrmann EP, Halfond AL, Powell NM, Collins MH, Rizvi T, Moertel CL, Ratner N, Largaespada DA.

Oncotarget. 2014 Mar 30;5(6):1502-14.

5.

Mouse models of cancer: Sleeping Beauty transposons for insertional mutagenesis screens and reverse genetic studies.

Tschida BR, Largaespada DA, Keng VW.

Semin Cell Dev Biol. 2014 Mar;27:86-95. doi: 10.1016/j.semcdb.2014.01.006. Epub 2014 Jan 24. Review.

6.

Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor.

Du X, Yang J, Ylipää A, Zhu Z.

J Hematol Oncol. 2013 Dec 17;6:93. doi: 10.1186/1756-8722-6-93.

7.

Survivin expression and prognostic significance in pediatric malignant peripheral nerve sheath tumors (MPNST).

Alaggio R, Turrini R, Boldrin D, Merlo A, Gambini C, Ferrari A, Dall'igna P, Coffin CM, Martines A, Bonaldi L, De Salvo GL, Zanovello P, Rosato A.

PLoS One. 2013 Nov 26;8(11):e80456. doi: 10.1371/journal.pone.0080456. eCollection 2013.

8.

Activated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated Proteins.

Mattingly RR.

ISRN Oncol. 2013 Oct 31;2013:536529. doi: 10.1155/2013/536529. eCollection 2013. Review.

9.

Neurofibromatosis: chronological history and current issues.

Antônio JR, Goloni-Bertollo EM, Trídico LA.

An Bras Dermatol. 2013 May-Jun;88(3):329-43. doi: 10.1590/abd1806-4841.20132125.

10.

Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.

Watson AL, Rahrmann EP, Moriarity BS, Choi K, Conboy CB, Greeley AD, Halfond AL, Anderson LK, Wahl BR, Keng VW, Rizzardi AE, Forster CL, Collins MH, Sarver AL, Wallace MR, Schmechel SC, Ratner N, Largaespada DA.

Cancer Discov. 2013 Jun;3(6):674-89. doi: 10.1158/2159-8290.CD-13-0081. Epub 2013 Mar 27.

11.

Optimizing biologically targeted clinical trials for neurofibromatosis.

Gutmann DH, Blakeley JO, Korf BR, Packer RJ.

Expert Opin Investig Drugs. 2013 Apr;22(4):443-62. doi: 10.1517/13543784.2013.772979. Epub 2013 Feb 21. Review.

12.

Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis.

Kazmi SJ, Byer SJ, Eckert JM, Turk AN, Huijbregts RP, Brossier NM, Grizzle WE, Mikhail FM, Roth KA, Carroll SL.

Am J Pathol. 2013 Mar;182(3):646-67. doi: 10.1016/j.ajpath.2012.11.017. Epub 2013 Jan 13.

13.

EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors.

Wu J, Patmore DM, Jousma E, Eaves DW, Breving K, Patel AV, Schwartz EB, Fuchs JR, Cripe TP, Stemmer-Rachamimov AO, Ratner N.

Oncogene. 2014 Jan 9;33(2):173-80. doi: 10.1038/onc.2012.579. Epub 2013 Jan 14.

14.

MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.

Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME, Eaves D, Widemann B, Kim MO, Dombi E, Sabo J, Hardiman Dudley A, Niwa-Kawakita M, Page GP, Giovannini M, Aronow BJ, Cripe TP, Ratner N.

J Clin Invest. 2013 Jan;123(1):340-7. doi: 10.1172/JCI60578. Epub 2012 Dec 10.

15.

Molecular control of Schwann cell migration along peripheral axons: keep moving!

Heermann S, Schwab MH.

Cell Adh Migr. 2013 Jan-Feb;7(1):18-22. doi: 10.4161/cam.22123. Epub 2012 Oct 17.

16.

Skin-derived precursors as a source of progenitors for cutaneous nerve regeneration.

Chen Z, Pradhan S, Liu C, Le LQ.

Stem Cells. 2012 Oct;30(10):2261-70. doi: 10.1002/stem.1186.

17.

Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.

Patel AV, Eaves D, Jessen WJ, Rizvi TA, Ecsedy JA, Qian MG, Aronow BJ, Perentesis JP, Serra E, Cripe TP, Miller SJ, Ratner N.

Clin Cancer Res. 2012 Sep 15;18(18):5020-30. doi: 10.1158/1078-0432.CCR-12-1072. Epub 2012 Jul 18.

18.

Perioperative management of neurofibromatosis type 1.

Fox CJ, Tomajian S, Kaye AJ, Russo S, Abadie JV, Kaye AD.

Ochsner J. 2012 Summer;12(2):111-21.

19.

PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors.

Keng VW, Rahrmann EP, Watson AL, Tschida BR, Moertel CL, Jessen WJ, Rizvi TA, Collins MH, Ratner N, Largaespada DA.

Cancer Res. 2012 Jul 1;72(13):3405-13. doi: 10.1158/0008-5472.CAN-11-4092. Epub 2012 Jun 14.

20.

Oncogene Mutation Survey in MPNST Cell Lines Enhances the Dominant Role of Hyperactive Ras in NF1 Associated Pro-Survival and Malignancy.

Sun D, Tainsky MA, Haddad R.

Transl Oncogenomics. 2012;5:1-7. doi: 10.4137/TOG.S8830. Epub 2012 Jan 18.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk